|Bid||136.75 x 1000|
|Ask||136.80 x 1100|
|Day's Range||134.03 - 136.94|
|52 Week Range||113.52 - 184.00|
|Beta (3Y Monthly)||1.09|
|PE Ratio (TTM)||18.75|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||171.88|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
The Food and Drug Administration approved Jazz Pharmaceuticals' new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea. Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval. Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has about 160 employees.
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc's treatment for patients with a form of sleep disorder, the company said on Wednesday. The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
D.A. Davidson initiating Lyft as buyGoldman Sachs downgrading Monster Beverage to neutral from buyJefferies downgrading Sony to hold from buyEvercore ISI initiating Costco as outperformEvercore ISI initiating Home Depot as outperformEvercore ISI initiating Bed, Bath & Beyond as underperformMizuho downgrading Wendy's to neutral from buyMizuho downgrading YUM Brands to underperform from neutralSunTrust initiating Allergan as buySunTrust initiating Jazz Pharmaceuticals as buyJ.
Jazz is seeking approval for solriamfetol for both excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea.
The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
This bull market, after breaking longevity records in August of last year, is about to celebrate its 10th birthday. The current run, which started from the market low on March 9, 2009, has lifted the Standard & Poor's 500-stock index by more than 300%. That includes escaping what looked to be a brewing bear market during the final quarter of 2018.Not all stocks have performed equally over the course of the past decade, of course. Indeed, the disparity between the market's top performers and its bottom dwellers is shockingly wide. Some companies saw their shares crumble by more than 90%, while other stocks exploded by several thousand percent.Granted, those ultra-big winners are outliers, but more stocks have dished out quadruple-digit gains since early 2009 than you might think.Here are the stock market's 10 biggest winners for the past 10 years, and its 10 biggest losers. We've evaluated the entire Russell 1000 Index, which consists of 1,000 of the largest companies on U.S. exchanges. In all cases, remember that past performance is no guarantee of future results; some losers are in recovery mode, while some winners are unwinding their big moves. SEE ALSO: The 25 Best S&P; 500 Stocks of the Past 50 Years
DUBLIN, March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 26) AstraZeneca plc (NYSE: AZN )(announced positive results ...
Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.
Jazz Pharmaceuticals Plc. rallied more than 9% in the extended session Tuesday after the biotech company topped Wall Street views for its fourth quarter. Jazz said it earned $160 million, or $2.64 a share, in the quarter, compared with $232.2 million, or $3.79 a share, in the fourth quarter of 2017. Adjusted for one-time items, the company earned $220 million, or $3.64 a share, compared with $180.5 million, or $2.95 a share, a year ago. Revenue rose to $476 million, compared with $436 million a year ago. Analysts polled by FactSet had expected adjusted earnings $3.02 a share on sales of $460 million. Jazz said it expects revenue between $2.05 billion and $2.13 billion this year. The stock ended the regular trading day up 1.2%.
Total Revenues Increased 17% to $1.9 Billion in 2018 GAAP Diluted EPS of $7.30 ; Adjusted Diluted EPS of $13.70 Launched Vyxeos for AML in the EU and Initiated Broad Development Program Received U.S. Approval ...
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 ...
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.